Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Christopher J. Maddage
MORAb-202, an Antibody Drug Conjugate Utilizing Humanized Anti-Human FRa Farletuzumab and the Microtubule-Targeting Agent Eribulin, Has Potent Anti-Tumor Activity
Molecular Cancer Therapeutics
Cancer Research
Oncology
Related publications
Novel Antibody-Drug Conjugate With Anti-Cd26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis
Cancers
Cancer Research
Oncology
Structural Characterization of a Potent Humanized Anti-Cd38 Antibody in Phase I
Acta Crystallographica Section A: Foundations and Advances
Materials Science
Condensed Matter Physics
Theoretical Chemistry
Biochemistry
Structural Biology
Inorganic Chemistry
Physical
Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-Ox40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity
Cell Reports
Biochemistry
Genetics
Molecular Biology
Anti-Tumor Activity of an Anti-Endoglin Monoclonal Antibody Is Enhanced in Immunocompetent Mice
International Journal of Cancer
Cancer Research
Oncology
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
Cancer Research
Cancer Research
Oncology
A Phase I Study of Farletuzumab, a Humanized Anti-Folate Receptor Α Monoclonal Antibody, in Patients With Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
Synergistic Anti-Tumor Therapy by a Comb-Like Multifunctional Antibody Nanoarray With Exceptionally Potent Activity
Scientific Reports
Multidisciplinary
Anti-Ccr7 Therapy Exerts a Potent Anti-Tumor Activity in a Xenograft Model of Human Mantle Cell Lymphoma
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Preclinical Antilymphoma Activity of a Humanized Anti-Cd40 Monoclonal Antibody, SGN-40
Cancer Research
Cancer Research
Oncology
